Compare SNT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNT | PLRX |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.6M | 74.9M |
| IPO Year | 2023 | 2020 |
| Metric | SNT | PLRX |
|---|---|---|
| Price | $2.55 | $1.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 39.8K | ★ 495.8K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.29 | $1.09 |
| 52 Week High | $5.34 | $1.95 |
| Indicator | SNT | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 43.49 |
| Support Level | N/A | $1.14 |
| Resistance Level | $2.87 | $1.37 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 12.69 | 17.86 |
Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.